Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mantle cell lymphoma.

J J Densmore1, M E Williams

  • 1Department of Internal Medicine, Division of Hematology/Oncology, Box 800716, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Robust Bottom-Up Gold Filling of Deep Trenches and Gratings.

Journal of the Electrochemical Society·2023
Same author

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Solidification of Ni-Re Peritectic Alloys.

Metallurgical and materials transactions. A. Physical metallurgy and materials science·2020
Same author

Accelerated Bottom-Up Gold Filling of Metallized Trenches.

Journal of the Electrochemical Society·2020
Same author

Exploring the Limits of Bottom-Up Gold Filling to Fabricate Diffraction Gratings.

Journal of the Electrochemical Society·2020
Same author

An approach for the identification of exemplar sites for scaling up targeted field observations of benthic biogeochemistry in heterogeneous environments.

Biogeochemistry·2020

Mantle cell lymphoma (MCL) is an aggressive cancer with poor prognosis. Current treatments offer limited survival benefits, highlighting the need for clinical trials and novel therapeutic strategies.

Area of Science:

  • Hematology
  • Oncology
  • Cancer Research

Background:

  • Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin's lymphoma.
  • Current chemotherapeutic approaches for MCL are incurable, with median survival around 3 years.
  • There is no established standard of care, emphasizing the importance of clinical trials.

Purpose of the Study:

  • To review current treatment approaches for Mantle Cell Lymphoma.
  • To discuss the efficacy and limitations of existing therapies.
  • To underscore the significance of clinical trials for patients with MCL.

Main Methods:

  • Review of existing literature on Mantle Cell Lymphoma treatment.
  • Analysis of response rates and survival data for various therapeutic regimens.

Related Experiment Videos

  • Evaluation of stem cell transplantation and novel agents.

    • Main Results:

    • Chemotherapy regimens show response rates of 50-70% but do not prevent disease progression.
    • Autologous stem cell transplant improves progression-free survival but not overall survival.
    • Allogeneic transplant shows promise in young patients; agents like rituximab, fludarabine, and cladribine lack survival advantages over combination chemotherapy.

    Conclusions:

    • Mantle cell lymphoma remains an incurable malignancy with current standard treatments.
    • Clinical trial enrollment is crucial for patients with MCL due to the lack of a clear standard of care.
    • While some treatments prolong progression-free survival, none have demonstrated a significant overall survival benefit.